Trials / Completed
CompletedNCT05411133
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Arbele Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to find out: 1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2. To find out how study drug is broken down in the body 3. To know the effects of the study drug on the tumor.
Conditions
- Gastrointestinal Cancer
- Cholangiocarcinoma
- Liver Cancer
- Colorectal Adenocarcinoma
- Pancreatic Cancer
- Gastric Cancer
- Esophageal Adenocarcinoma
- Gastroesophageal Junction
- Gastrointestinal Neuroendocrine Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabotamig (ARB202) | Cabotamig (ARB202), Atezolizumab |
Timeline
- Start date
- 2022-05-30
- Primary completion
- 2025-07-23
- Completion
- 2025-07-23
- First posted
- 2022-06-09
- Last updated
- 2026-03-19
Locations
3 sites across 2 countries: Australia, Hong Kong
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05411133. Inclusion in this directory is not an endorsement.